(Circulation. 1999;100:2191.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
The T-Type Ca2+ Channel Blocker Mibefradil Prevents the Development of a Substrate for Atrial Fibrillation by Tachycardia-Induced Atrial Remodeling in Dogs
From the Department of Medicine and Research Center, Montreal Heart Institute and University of Montreal, Montreal, Quebec (S.F., A.B., B.T., S.N.), and the Department of Pharmacology and Therapeutics (S.N.), McGill University, Montreal, Quebec, Canada, and Hoffman–La Roche Pharmaceuticals (A.B.), Basel, Switzerland.
Correspondence to Dr Stanley Nattel, Research Center, Montreal Heart Institute, 5000 Belanger St E, Montreal, Quebec H1T 1C8, Canada. E-mail nattel{at}icm.umontreal.ca
Background—Ca2+ overload is believed to play a role in tachycardia-induced atrial electrophysiological remodeling. L-type Ca2+ channel blockers attenuate effective refractory period (ERP) changes caused by 24 hours of atrial tachycardia but may not substantially alter atrial fibrillation (AF) inducibility. This study assessed the effects of the T-type Ca2+ channel blocker mibefradil on tachycardia-induced atrial remodeling.
Methods and Results—Dogs subjected to rapid atrial pacing (400 bpm) for 7 days were treated with mibefradil (100 mg/d, n=8) or matching placebo (n=10) in blinded fashion. Radiofrequency ablation of atrioventricular conduction and ventricular pacing were used to control ventricular rate. Placebo dogs showed significant decreases in atrial ERP (76±5 ms at a cycle length of 300 ms) and increases in ERP heterogeneity (27.7±2.4%), AF duration (414±232 seconds), and AF inducibility by single extrastimuli (41±10% of sites) compared with 10 unpaced control dogs (ERP 114±3 ms, ERP heterogeneity 13.8±0.9%, AF duration 7±3 seconds, AF inducibility 1.9±1.0% of sites). The changes caused by atrial tachycardia were strongly attenuated in mibefradil dogs, with ERPs averaging 102±7 ms, ERP heterogeneity 18.8±1.4%, AF duration 3±1 seconds, and AF inducibility 9.6±4.0% of sites. Among mibefradil-treated dogs, ERP, AF duration, and inducibility correlated with plasma drug concentration. Acute mibefradil administration did not alter ERP or AF.
Conclusions—Mibefradil, a drug with strong T-type Ca2+ channel blocking properties, prevents AF-promoting electrophysiological remodeling by atrial tachycardia. These findings have important potential implications for the mechanisms of tachycardia-induced atrial remodeling and demonstrate the feasibility of preventing electrical remodeling caused by several days of atrial tachycardia.
Key Words: arrhythmia • antiarrhythmia agents • electrophysiology • calcium channels
This article has been cited by other articles:
 |
|
 |
|
  M. Shimano, Y. Inden, Y. Tsuji, H. Kamiya, T. Uchikawa, R. Shibata, and T. Murohara Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation Europace, June 11, 2008; (2008) eun140v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Savelieva and J. Camm Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches Europace, June 1, 2008; 10(6): 647 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J.J.M. Brundel, L. Ke, A.-J. Dijkhuis, X. Qi, A. Shiroshita-Takeshita, S. Nattel, R. H. Henning, and H. H. Kampinga Heat shock proteins as molecular targets for intervention in atrial fibrillation Cardiovasc Res, June 1, 2008; 78(3): 422 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nattel, B. Burstein, and D. Dobrev Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications Circ Arrhythmia Electrophysiol, April 1, 2008; 1(1): 62 - 73. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. J. M. Brundel, A. Shiroshita-Takeshita, X. Qi, Y.-H. Yeh, D. Chartier, I. C. van Gelder, R. H. Henning, H. H. Kampinga, and S. Nattel Induction of Heat Shock Response Protects the Heart Against Atrial Fibrillation Circ. Res., December 8, 2006; 99(12): 1394 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Freeze, M. M. McNulty, and D. A. Hanck State-Dependent Verapamil Block of the Cloned Human Cav3.1 T-Type Ca2+ Channel Mol. Pharmacol., August 1, 2006; 70(2): 718 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Yamashita, T. Kaku, T. Uchino, S. Isomoto, H. Yoshimatsu, and K. Ono Short- and Long-Term Amiodarone Treatments Regulate Cav3.2 Low-Voltage-Activated T-type Ca2+ Channel through Distinct Mechanisms Mol. Pharmacol., May 1, 2006; 69(5): 1684 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Ehrlich, S. H. Hohnloser, and S. Nattel Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence Eur. Heart J., March 1, 2006; 27(5): 512 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shiroshita-Takeshita, B. J.J.M. Brundel, J. Lavoie, and S. Nattel Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs Cardiovasc Res, March 1, 2006; 69(4): 865 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Gaborit, M. Steenman, G. Lamirault, N. Le Meur, S. Le Bouter, G. Lande, J. Leger, F. Charpentier, T. Christ, D. Dobrev, et al. Human Atrial Ion Channel and Transporter Subunit Gene-Expression Remodeling Associated With Valvular Heart Disease and Atrial Fibrillation Circulation, July 26, 2005; 112(4): 471 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shiroshita-Takeshita, G. Schram, J. Lavoie, and S. Nattel Effect of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation Promotion by Atrial-Tachycardia Remodeling in Dogs Circulation, October 19, 2004; 110(16): 2313 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nattel Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy? Can. Med. Assoc. J., September 28, 2004; 171(7): 752 - 753. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Niwa, K. Yasui, T. Opthof, H. Takemura, A. Shimizu, M. Horiba, J.-K. Lee, H. Honjo, K. Kamiya, and I. Kodama Cav3.2 subunit underlies the functional T-type Ca2+ channel in murine hearts during the embryonic period Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2257 - H2263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J.J.M Brundel, H. H Kampinga, and R. H Henning Calpain inhibition prevents pacing-induced cellular remodeling in a HL-1 myocyte model for atrial fibrillation Cardiovasc Res, June 1, 2004; 62(3): 521 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wasson, H. K. Reddy, and M. L. Dohrmann Current Perspectives of Electrical Remodeling and Its Therapeutic Implications Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2004; 9(2): 129 - 144. [Abstract] [PDF]
|
|
|
|
|
|
L. Ferron, V. Capuano, Y. Ruchon, E. Deroubaix, A. Coulombe, and J.-F. Renaud Angiotensin II Signaling Pathways Mediate Expression of Cardiac T-Type Calcium Channels Circ. Res., December 12, 2003; 93(12): 1241 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Sanguinetti and P. B. Bennett Antiarrhythmic Drug Target Choices and Screening Circ. Res., September 19, 2003; 93(6): 491 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kumagai, H. Nakashima, H. Urata, N. Gondo, K. Arakawa, and K. Saku Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2197 - 2204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shinagawa, A. Shiroshita-Takeshita, G. Schram, and S. Nattel Effects of Antiarrhythmic Drugs on Fibrillation in the Remodeled Atrium: Insights Into the Mechanism of the Superior Efficacy of Amiodarone Circulation, March 18, 2003; 107(10): 1440 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Khairy and S. Nattel New insights into the mechanisms and management of atrial fibrillation Can. Med. Assoc. J., October 29, 2002; 167(9): 1012 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schram, M. Pourrier, P. Melnyk, and S. Nattel Differential Distribution of Cardiac Ion Channel Expression as a Basis for Regional Specialization in Electrical Function Circ. Res., May 17, 2002; 90(9): 939 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Biffi, G Boriani, M Bartolotti, L Bacchi Reggiani, R Zannoli, and A Branzi Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters Heart, May 1, 2002; 87(5): 443 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F Bosch and S. Nattel Cellular electrophysiology of atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 259 - 269. [Full Text] [PDF]
|
|
|
|
|
|
B. J.J.M. Brundel, R. H. Henning, H. H. Kampinga, I. C. Van Gelder, and H. J.G.M. Crijns Molecular mechanisms of remodeling in human atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 315 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nattel Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res, May 1, 2002; 54(2): 347 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shinagawa, H. Mitamura, S. Ogawa, and S. Nattel Effects of inhibiting Na+/H+-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling Cardiovasc Res, May 1, 2002; 54(2): 438 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kurita, H. Mitamura, A. Shiroshita-Takeshita, A. Yamane, M. Ieda, O. Kinebuchi, T. Sato, S. Miyoshi, M. Hara, S. Takatsuki, et al. Daily oral verapamil before but not after rapid atrial excitation prevents electrical remodeling Cardiovasc Res, May 1, 2002; 54(2): 447 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Eur. Heart J., October 2, 2001; 22(20): 1852 - 1923. [PDF]
|
|
|
|
|
|
S.P Fynn, D.M Todd, W.J.C Hobbs, K.L Armstrong, and C.J Garratt Role of dispersion of atrial refractoriness in the recurrence of clinical atrial fibrillation. A manifestation of atrial electrical remodelling in humans? Eur. Heart J., October 1, 2001; 22(19): 1822 - 1834. [Abstract] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1266 - 1266. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Carnes, M. K. Chung, T. Nakayama, H. Nakayama, R. S. Baliga, S. Piao, A. Kanderian, S. Pavia, R. L. Hamlin, P. M. McCarthy, et al. Ascorbate Attenuates Atrial Pacing-Induced Peroxynitrite Formation and Electrical Remodeling and Decreases the Incidence of Postoperative Atrial Fibrillation Circ. Res., September 14, 2001; 89 (6): e32 - e38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Derakhchan, C. Villemaire, M. Talajic, and S. Nattel The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF Cardiovasc Res, April 1, 2001; 50(1): 75 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Benardeau, S. Fareh, and S. Nattel Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs Cardiovasc Res, April 1, 2001; 50(1): 85 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fareh, A. Benardeau, and S. Nattel Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs Cardiovasc Res, March 1, 2001; 49(4): 762 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Altemose, D. P. Zipes, J. Weksler, J. M. Miller, and J. E. Olgin Inhibition of the Na+/H+ Exchanger Delays the Development of Rapid Pacing-Induced Atrial Contractile Dysfunction Circulation, February 6, 2001; 103(5): 762 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nattel and D. Li Ionic Remodeling in the Heart : Pathophysiological Significance and New Therapeutic Opportunities for Atrial Fibrillation Circ. Res., September 15, 2000; 87(6): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.J. Garratt and S.P. Fynn Atrial electrical remodelling and atrial fibrillation QJM, September 1, 2000; 93(9): 563 - 565. [Full Text] [PDF]
|
|
|
|
|
|
B. Huang, D. Qin, L. Deng, M. Boutjdir, and N. El-Sherif Reexpression of T-type Ca2+ channel gene and current in post-infarction remodeled rat left ventricle Cardiovasc Res, June 1, 2000; 46(3): 442 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nargeot A Tale of Two (Calcium) Channels Circ. Res., March 31, 2000; 86(6): 613 - 615. [Full Text] [PDF]
|
|